Andrew Singleton

List of Publications by Citations

164 papers	22,822 citations	64 h-index	150 g-index
185 ext. papers	26,312 ext. citations	9.9 avg, IF	5.82 L-index

#	Paper	IF	Citations
164	A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*, **2011**, 72, 257-68	13.9	3018
163	TREM2 variants in Alzheimer's disease. *New England Journal of Medicine*, **2013**, 368, 117-27	59.2	1805
162	New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nature Genetics*, **2010**, 42, 105-16	36.3	1673
161	Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* , **2011**, 478, 103-9	50.4	1564
160	The Parkinson Progression Marker Initiative (PPMI). *Progress in Neurobiology*, **2011**, 95, 629-35	10.9	793
159	Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. *Neurobiology of Disease*, **2006**, 23, 329-41	7.5	608
158	Common genetic variants influence human subcortical brain structures. *Nature*, **2015**, 520, 224-9	50.4	601
157	Genomewide association studies and human disease. *New England Journal of Medicine*, **2009**, 360, 1759-68	59.2	564
156	Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nature Genetics*, **2010**, 42, 142-8	36.3	527
155	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. *Brain*, **2009**, 132, 1783-94	11.2	488
154	Lewy bodies and parkinsonism in families with parkin mutations. *Annals of Neurology*, **2001**, 50, 293-300	9.4	425
153	Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nature Genetics*, **2011**, 43, 1005-11	36.3	338
152	Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. *American Journal of Human Genetics*, **2008**, 83, 520-8	11	336
151	A genome-wide association study identifies protein quantitative trait loci (pQTLs). *PLoS Genetics*, **2008**, 4, e1000072	6	331
150	Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurology, The*, **2006**, 5, 911-6	24.1	323
149	Characterization of PLA2G6 as a locus for dystonia-parkinsonism. *Annals of Neurology*, **2009**, 65, 19-23	9.4	320
148	Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. *PLoS Genetics*, **2009**, 5, e1000338	6	300

147	A common LRRK2 mutation in idiopathic Parkinson disease. *Lancet, The*, **2005**, 365, 415-6	40	283
146	Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. *JAMA Neurology*, **2013**, 70, 78-84	17.2	257
145	Association of cerebrospinal fluid amyloid 1-42, T-tau, P-tau181, and synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurology*, **2013**, 70, 1277-87	17.2	252
144	Genetics of Parkinson disease and parkinsonism. *Annals of Neurology*, **2006**, 60, 389-98	9.4	252
143	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. *American Journal of Human Genetics*, **2016**, 98, 500-513	11	225
142	Early-onset Parkinson disease caused by a compound heterozygous DJ-1 mutation. *Annals of Neurology*, **2003**, 54, 271-4	9.4	202
141	Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. *Human Molecular Genetics*, **2007**, 16, 1-14	5.6	199
140	Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. *American Journal of Human Genetics*, **2009**, 84, 477-82	11	193
139	GWAS of longevity in CHARGE consortium confirms APOE and FOXO3 candidacy. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2015**, 70, 110-8	6.4	188
138	A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. *American Journal of Human Genetics*, **2009**, 84, 558-66	11	181
137	Common variation in the beta-carotene 15,15-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. *American Journal of Human Genetics*, **2009**, 84, 123-33	11	175
136	Novel genetic loci associated with hippocampal volume. *Nature Communications*, **2017**, 8, 13624	17.4	173
135	Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. *Lancet Neurology, The*, **2007**, 6, 322-8	24.1	172
134	Human aging is characterized by focused changes in gene expression and deregulation of alternative splicing. *Aging Cell*, **2011**, 10, 868-78	9.9	163
133	Genetic screening of Alzheimer disease genes in Iberian and African samples yields novel mutations in presenilins and APP. *Neurobiology of Aging*, **2010**, 31, 725-31	5.6	162
132	A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. *Lancet Neurology, The*, **2007**, 6, 414-20	24.1	154
131	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152
130	Parkinson disease and synuclein expression. *Movement Disorders*, **2011**, 26, 2160-8	7	149

129	Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nature Neuroscience*, **2016**, 19, 1569-1582	25.5	147
128	Genetic screening for a single common LRRK2 mutation in familial Parkinson disease. *Lancet, The*, **2005**, 365, 410-2	40	145
127	The Parkinson progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1460-1477	5.3	142
126	CSF biomarkers associated with disease heterogeneity in early Parkinson disease: the Parkinson Progression Markers Initiative study. *Acta Neuropathologica*, **2016**, 131, 935-49	14.3	138
125	Whole genome analyses suggest ischemic stroke and heart disease share an association with polymorphisms on chromosome 9p21. *Stroke*, **2008**, 39, 1586-9	6.7	138
124	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121
123	A genome-wide association analysis of serum iron concentrations. *Blood*, **2010**, 115, 94-6	2.2	117
122	Spinocerebellar ataxia type 3 phenotypically resembling parkinson disease in a black family. *Archives of Neurology*, **2001**, 58, 296-9		117
121	Emerging pathways in genetic Parkinson disease: Potential role of ceramide metabolism in Lewy body disease. *FEBS Journal*, **2008**, 275, 5767-73	5.7	109
120	Estimating the causal influence of body mass index on risk of Parkinson disease: A Mendelian randomisation study. *PLoS Medicine*, **2017**, 14, e1002314	11.6	93
119	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis. *Human Molecular Genetics*, **2009**, 18, 1524-32	5.6	91
118	The dardarin G 2019 S mutation is a common cause of Parkinson disease but not other neurodegenerative diseases. *Neuroscience Letters*, **2005**, 389, 137-9	3.3	89
117	The tau H2 haplotype is almost exclusively Caucasian in origin. *Neuroscience Letters*, **2004**, 369, 183-5	3.3	88
116	Genes and parkinsonism. *Lancet Neurology, The*, **2003**, 2, 221-8	24.1	85
115	G2019S dardarin substitution is a common cause of Parkinson disease in a Portuguese cohort. *Movement Disorders*, **2005**, 20, 1653-5	7	85
114	Tyrosinase exacerbates dopamine toxicity but is not genetically associated with Parkinson disease. *Journal of Neurochemistry*, **2005**, 93, 246-56	6	84
113	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. *PLoS ONE*, **2017**, 12, e0175674	3.7	84
112	A meta-analysis of gene expression signatures of blood pressure and hypertension. *PLoS Genetics*, **2015**, 11, e1005035	6	83

111	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. *Neurobiology of Aging*, **2009**, 30, 1515-7	5.6	79
110	Application of genome-wide single nucleotide polymorphism typing: simple association and beyond. *PLoS Genetics*, **2006**, 2, e150	6	79
109	Human ataxias: a genetic dissection of inositol triphosphate receptor (ITPR1)-dependent signaling. *Trends in Neurosciences*, **2010**, 33, 211-9	13.3	76
108	The law of mass action applied to neurodegenerative disease: a hypothesis concerning the etiology and pathogenesis of complex diseases. *Human Molecular Genetics*, **2004**, 13 Spec No 1, R123-6	5.6	74
107	Phenomenology of "Lubag" or X-linked dystonia-parkinsonism. *Movement Disorders*, **2002**, 17, 1271-7	7	74
106	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. *Movement Disorders*, **2018**, 33, 771-782	7	73
105	Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1008.e17-23	5.6	72
104	Parkinson's disease and dementia with Lewy bodies: a difference in dose?. *Lancet, The*, **2004**, 364, 1105-7	40	70
103	Torsin A haplotype predisposes to idiopathic dystonia. *Annals of Neurology*, **2005**, 57, 765-7	9.4	70
102	Ethnic differences in the expression of neurodegenerative disease: Machado-Joseph disease in Africans and Caucasians. *Movement Disorders*, **2002**, 17, 1068-71	7	69
101	The Evolution of Genetics: Alzheimer's and Parkinson's Diseases. *Neuron*, **2016**, 90, 1154-1163	13.9	68
100	Primary hyperhidrosis--evidence for autosomal dominant inheritance. *Clinical Autonomic Research*, **2003**, 13, 96-8	4.3	64
99	Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. *BMC Neurology*, **2006**, 6, 44	3.1	61
98	A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci. *Human Molecular Genetics*, **2011**, 20, R158-62	5.6	60
97	Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. *Movement Disorders*, **2004**, 19, 796-800	7	60
96	Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. *Movement Disorders*, **2006**, 21, 282-3	7	58
95	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. *Current Opinion in Neurology*, **2005**, 18, 706-11	7.1	56
94	SCA15 due to large ITPR1 deletions in a cohort of 333 white families with dominant ataxia. *Archives of Neurology*, **2011**, 68, 637-43		54

93	TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis. *PLoS ONE*, **2008**, 3, e2450	3.7	50
92	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiology of Aging*, **2016**, 38, 214.e7-214.e10	5.6	49
91	Extracting Vertical Displacement Rates in Shanghai (China) with Multi-Platform SAR Images. *Remote Sensing*, **2015**, 7, 9542-9562	5	49
90	Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. *American Journal of Human Genetics*, **2006**, 78, 1082-4; author reply 1092-4	11	49
89	Next generation sequencing techniques in neurological diseases: redefining clinical and molecular associations. *Human Molecular Genetics*, **2014**, 23, R47-53	5.6	48
88	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. *Npj Parkinson's Disease*, **2019**, 5, 8	9.7	47
87	Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. *Movement Disorders*, **2009**, 24, 662-6	7	47
86	Advancing age is associated with gene expression changes resembling mTOR inhibition: evidence from two human populations. *Mechanisms of Ageing and Development*, **2012**, 133, 556-62	5.6	46
85	Sequential use of transcriptional profiling, expression quantitative trait mapping, and gene association implicates MMP20 in human kidney aging. *PLoS Genetics*, **2009**, 5, e1000685	6	46
84	Genetic variability in CLU and its association with Alzheimer's disease. *PLoS ONE*, **2010**, 5, e9510	3.7	46
83	Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2881.e1-2881.e6	5.6	45
82	Analysis of Nigerians with apparently sporadic Parkinson disease for mutations in LRRK2, PRKN and ATXN3. *PLoS ONE*, **2008**, 3, e3421	3.7	45
81	Candidate gene polymorphisms for ischemic stroke. *Stroke*, **2009**, 40, 3436-42	6.7	44
80	Genomewide SNP assay reveals mutations underlying Parkinson disease. *Human Mutation*, **2008**, 29, 315-22	4.7	44
79	Genome-wide association studies in neurological disorders. *Lancet Neurology, The*, **2008**, 7, 1067-72	24.1	43
78	Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset. *Movement Disorders*, **2006**, 21, 534-9	7	42
77	Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. *European Journal of Human Genetics*, **2001**, 9, 659-66	5.3	42
76	A rare truncating mutation in ADH1C (G78Stop) shows significant association with Parkinson disease in a large international sample. *Archives of Neurology*, **2005**, 62, 74-8		41

75	Linkage, whole genome sequence, and biological data implicate variants in RAB10 in Alzheimer disease resilience. *Genome Medicine*, **2017**, 9, 100	14.4	40
74	Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. *Annals of Human Genetics*, **2013**, 77, 85-105	2.2	40
73	Identical twins with the C9orf72 repeat expansion are discordant for ALS. *Neurology*, **2014**, 83, 1476-8	6.5	39
72	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson Progression Markers Initiative (PPMI): a cross-sectional study. *Lancet Neurology, The*, **2020**, 19, 71-80	24.1	37
71	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. *Neurobiology of Aging*, **2015**, 36, 2904.e13-26	5.6	34
70	An evaluation of the Team Objective Structured Clinical Examination (TOSCE). *Medical Education*, **1999**, 33, 34-41	3.7	33
69	Genetics of early-onset Parkinson disease in Finland: exome sequencing and genome-wide association study. *Neurobiology of Aging*, **2017**, 53, 195.e7-195.e10	5.6	32
68	Shared biological pathways for frailty and cognitive impairment: A systematic review. *Ageing Research Reviews*, **2018**, 47, 149-158	12	32
67	The TOR1A polymorphism rs1182 and the risk of spread in primary blepharospasm. *Movement Disorders*, **2009**, 24, 613-6	7	32
66	Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2. *BMC Neurology*, **2008**, 8, 1	3.1	32
65	Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients. *Neurobiology of Aging*, **2012**, 33, 1850.e17-27	5.6	31
64	Genetic susceptibility in Parkinson disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2009**, 1792, 597-603	6.9	30
63	Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by -synuclein triplication (Iowa kindred). *Movement Disorders*, **2011**, 26, 2134-6	7	27
62	NOTCH3 variants and risk of ischemic stroke. *PLoS ONE*, **2013**, 8, e75035	3.7	27
61	A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson disease. *Human Molecular Genetics*, **2015**, 24, 6711-20	5.6	26
60	Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V and p.S230R) in British early-onset Alzheimer disease. *Neurobiology of Aging*, **2014**, 35, 2422.e13-6	5.6	26
59	Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years. *Movement Disorders*, **2005**, 20, 479-484	7	26
58	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer disease. *Neurobiology of Aging*, **2018**, 62, 244.e1-244.e8	5.6	25

57	Novel progranulin mutation: screening for PGRN mutations in a Portuguese series of FTD/CBS cases. *Movement Disorders*, **2008**, 23, 1269-73	7	25
56	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. *Brain*, **2018**, 141, 2895-2907	11.2	25
55	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. *Neurobiology of Aging*, **2015**, 36, 545.e9-14	5.6	24
54	Anatomy of Subsidence in Tianjin from Time Series InSAR. *Remote Sensing*, **2016**, 8, 266	5	24
53	Genome-wide assessment of Parkinson's disease in a Southern Spanish population. *Neurobiology of Aging*, **2016**, 45, 213.e3-213.e9	5.6	23
52	X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype?. *Movement Disorders*, **2002**, 17, 200-2	7	22
51	A thorough assessment of benign genetic variability in GRN and MAPT. *Human Mutation*, **2010**, 31, E1126-40	4.7	21
50	Kinase signaling pathways as potential targets in the treatment of Parkinson's disease. *Expert Review of Proteomics*, **2007**, 4, 783-92	4.2	20
49	Paraoxonase 1 (PON1) gene polymorphisms and Parkinson's disease in a Finnish population. *Neuroscience Letters*, **2004**, 367, 168-70	3.3	20
48	Whole blood gene expression and interleukin-6 levels. *Genomics*, **2014**, 104, 490-5	4.3	19
47	A consanguineous Turkish family with early-onset Parkinson's disease and an exon 4 parkin deletion. *Movement Disorders*, **2004**, 19, 812-816	7	19
46	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. *Movement Disorders*, **2019**, 34, 1851-1863	7	18
45	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. *Movement Disorders*, **2020**, 35, 833-844	7	18
44	Ethnic differences and disease phenotypes. *Science*, **2003**, 300, 739-40	33.3	18
43	Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2005**, 133B, 120-3	3.5	18
42	Gene expression markers of age-related inflammation in two human cohorts. *Experimental Gerontology*, **2015**, 70, 37-45	4.5	17
41	Linkage disequilibrium and association analysis of alpha-synuclein and alcohol and drug dependence in two American Indian populations. *Alcoholism: Clinical and Experimental Research*, **2007**, 31, 546-54	3.7	17
40	Mutation Frequency of the Major Frontotemporal Dementia Genes, MAPT, GRN and C9ORF72 in a Turkish Cohort of Dementia Patients. *PLoS ONE*, **2016**, 11, e0162592	3.7	16

39	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.5	15
38	Multiple system atrophy: the application of genetics in understanding etiology. *Clinical Autonomic Research*, **2015**, 25, 19-36	4.3	15
37	Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array. *Neurobiology of Aging*, **2017**, 49, 215.e1-215.e8	5.6	15
36	Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. *Annals of Neurology*, **2008**, 64, 348-52	9.4	15
35	Smell testing is abnormal in Q ubag Q or X-linked dystonia-parkinsonism: a pilot study. *Parkinsonism and Related Disorders*, **2004**, 10, 407-10	3.6	15
34	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *Acta Neuropathologica Communications*, **2020**, 8, 5	7.3	15
33	APOE and A P gene variation in cortical and cerebrovascular amyloid- pathology and Alzheimer's disease: a population-based analysis. *Journal of Alzheimer s Disease*, **2011**, 26, 377-85	4.3	14
32	Anticholinergic Drug Induced Cognitive and Physical Impairment: Results from the InCHIANTI Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2020**, 75, 995-1002	6.4	14
31	Genomic risk profiling of ischemic stroke: results of an international genome-wide association meta-analysis. *PLoS ONE*, **2011**, 6, e23161	3.7	12
30	Mutation at the SCA17 locus is not a common cause of parkinsonism. *Parkinsonism and Related Disorders*, **2003**, 9, 317-20	3.6	12
29	Genetic and Phenotypic Basis of Autosomal Dominant Parkinson's Disease in a Large Multi-Center Cohort. *Frontiers in Neurology*, **2020**, 11, 682	4.1	12
28	Characterization of recessive Parkinson's disease in a large multicenter study. *Annals of Neurology*, **2020**, 88, 843	9.4	11
27	Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. *PLoS ONE*, **2007**, 2, e1254	3.7	11
26	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
25	The future of genetic analysis of neurological disorders. *Neurobiology of Disease*, **2000**, 7, 65-9	7.5	10
24	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. *Annals of Clinical and Translational Neurology*, **2020**, 7, 1816-1830	5.3	10
23	A comprehensive screening of copy number variability in dementia with Lewy bodies. *Neurobiology of Aging*, **2019**, 75, 223.e1-223.e10	5.6	10
22	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). *Parkinsonism and Related Disorders*, **2019**, 62, 201-209	3.6	9

21	Blepharospasm: A genetic screening study in 132 patients. *Parkinsonism and Related Disorders*, **2019**, 64, 315-318	3.6	9
20	Shared mechanisms for cognitive impairment and physical frailty: A model for complex systems. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12027	6	8
19	Whole-genome sequencing to understand the genetic architecture of common gene expression and biomarker phenotypes. *Human Molecular Genetics*, **2015**, 24, 1504-12	5.6	7
18	The HapMap: charting a course for genetic discovery in neurological diseases. *Archives of Neurology*, **2008**, 65, 319-21		7
17	No evidence for tau duplications in frontal temporal dementia families showing genetic linkage to the tau locus in which tau mutations have not been found. *Neuroscience Letters*, **2004**, 363, 99-101	3.3	7
16	A comprehensive assessment of benign genetic variability for neurodegenerative disorders		7
15	Peripheral GRN mRNA and Serum Progranulin Levels as a Potential Indicator for Both the Presence of Splice Site Mutations and Individuals at Risk for Frontotemporal Dementia. *Journal of Alzheimer's Disease*, **2019**, 67, 159-167	4.3	7
14	Splicing factor 3B1 hypomethylation is associated with altered SF3B1 transcript expression in older humans. *Mechanisms of Ageing and Development*, **2014**, 135, 50-6	5.6	5
13	Mutations in TYROBP are not a common cause of dementia in a Turkish cohort. *Neurobiology of Aging*, **2017**, 58, 240.e1-240.e3	5.6	5
12	Using Exome Sequencing to Reveal Mutations in TREM2 Presenting as a Frontotemporal Dementia□like Syndrome Without Bone Involvement. *JAMA Neurology*, **2012**, 1	17.2	5
11	Reporting and interpretation of genetic variants in cases and controls. *Neurology*, **2007**, 69, 111-2	6.5	5
10	A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's disease. *PLoS ONE*, **2017**, 12, e0178982	3.7	5
9	Genome-wide association studies and ALS: are we there yet?. *Lancet Neurology, The*, **2007**, 6, 841-3	24.1	4
8	Mutation of the Parkin gene in a Persian family: clinical progression over a 40-year period. *Movement Disorders*, **2005**, 20, 887-90	7	4
7	Effects of Multiple Genetic Loci on Age at□Onset in Frontotemporal Dementia. *Journal of Alzheimer's Disease*, **2017**, 56, 1271-1278	4.3	3
6	Prion genotypes in Central America suggest selection for the V129 allele. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2006**, 141B, 33-5	3.5	3
5	Susceptibility genes in movement disorders. *Movement Disorders*, **2008**, 23, 927-934	7	2
4	Exploring dementia and neuronal ceroid lipofuscinosis genes in 100 FTD-like patients from 6 towns and rural villages on the Adriatic Sea cost of Apulia. *Scientific Reports*, **2021**, 11, 6353	4.9	2

3	A simple and efficient algorithm for genome-wide homozygosity analysis in disease. *Molecular Systems Biology*, **2009**, 5, 304	12.2	1
2	Familiality in simple and complex disease. *Clinical Autonomic Research*, **2003**, 13, 88-90	4.3	1
1	Clinical Variability of -Associated Early-Onset Parkinsonism. *Frontiers in Neurology*, **2021**, 12, 648457	4.1	1